Stefan Roos
Overview
Explore the profile of Stefan Roos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
2479
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roos S, Dahlgren A, Mao Y, Pallin A, Stanisz A, Forsythe P, et al.
Neurogastroenterol Motil
. 2025 Mar;
:e70012.
PMID: 40033155
Background: Chronic constipation is a prevalent, burdensome gastrointestinal disorder whose etiology and pathophysiology remain poorly understood. Differences in the composition of the intestinal microbiota have been shown between constipated patients...
2.
Ermann Lundberg L, Mata Forsberg M, Lemanczyk J, Sverremark-Ekstrom E, Sandstrom C, Roos S, et al.
Microorganisms
. 2024 Oct;
12(10).
PMID: 39458367
Improved efficacy of probiotics can be achieved by using different strategies, including the optimization of production parameters. The impact of fermentation parameters on bacterial physiology is a frequently investigated topic,...
3.
Santos A, Duarte R, Duarte M, Arella F, Marques V, Roos S, et al.
Life Sci
. 2024 Aug;
354:122948.
PMID: 39117140
The gut-liver axis plays a pivotal role in maintaining body homeostasis. Disruption of the gut-liver axis is linked to a multitude of diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD)....
4.
Merenstein D, Tancredi D, Karl J, Krist A, Lenoir-Wijnkoop I, Reid G, et al.
Adv Nutr
. 2024 Jul;
15(8):100265.
PMID: 38977065
Probiotics are typically marketed as foods and dietary supplements, categories for products intended to maintain health in generally healthy populations and which, unlike drugs, cannot claim to treat or cure...
5.
Ermann Lundberg L, Pallabi Mishra P, Liu P, Mata Forsberg M, Sverremark-Ekstrom E, Grompone G, et al.
Appl Environ Microbiol
. 2024 Jun;
90(7):e0024724.
PMID: 38888338
Importance: By using probiotics that contain a combination of strains with synergistic properties, the likelihood of achieving beneficial interactions with the host can increase. In this study, we first performed...
6.
Ohnstedt E, Donas C, Parv K, Pang Y, Lofton Tomenius H, Carrasco Lopez M, et al.
Am J Physiol Gastrointest Liver Physiol
. 2024 May;
327(2):G140-G153.
PMID: 38780469
Treatments of colitis, inflammation of the intestine, rely on induction of immune suppression associated with systemic adverse events, including recurrent infections. This treatment strategy is specifically problematic in the increasing...
7.
Sendelius M, Axelsson J, Liu P, Roos S
J Ind Microbiol Biotechnol
. 2023 Nov;
50(1).
PMID: 37974056
Evaluating the safety of probiotic microorganisms is an important part of the development of probiotic products. In this study, we have performed a systematic safety assessment of Limosilactobacillus reuteri American...
8.
Li P, Roos S, Luo H, Ji B, Nielsen J
Metab Eng
. 2023 Jun;
79:1-13.
PMID: 37364774
Many studies have demonstrated that the gut microbiota is associated with human health and disease. Manipulation of the gut microbiota, e.g. supplementation of probiotics, has been suggested to be feasible,...
9.
Ohnstedt E, Vagesjo E, Fasth A, Lofton Tomenius H, Dahg P, Jonsson S, et al.
EClinicalMedicine
. 2023 May;
60:102014.
PMID: 37251631
Background: Impaired wound healing is a growing medical problem and very few approved drugs with documented clinical efficacy are available. CXCL12-expressing lactic acid bacteria, (ILP100-Topical), has been demonstrated to accelerate...
10.
Liu Y, Armbrister S, Okeugo B, Mills T, Daniel R, Oh J, et al.
Probiotics Antimicrob Proteins
. 2023 May;
15(4):1001-1013.
PMID: 37178405
Probiotic Limosilactobacillus reuteri DSM 17938 (DSM 17938) prolongs the survival of Treg-deficient scurfy (SF) mice and reduces multiorgan inflammation by a process requiring adenosine receptor 2A (A) on T cells....